BERLIN, May 10 (Reuters) – German pharmaceutical group BioNTech said on Monday it plans to establish a regional headquarters in Singapore and build a new plant there to manufacture its vaccines based on messenger RNA (mRNA) technology, an initiative with which it aims to expand your production network.
The biotech company said the Singapore plant will have an estimated annual production capacity of several hundred million doses of mRNA-based vaccines, based on the specific type, once it is operational in 2023.
BioNTech said its expansion plans are supported by the Singapore Economic Development Board and will increase the global supply of mRNA-based vaccines, establishing a production facility in Southeast Asia to rapidly respond to future pandemics.
“Having multiple nodes in our production network is an important strategic step in building our global production presence and capabilities,” said Ugur Sahin, CEO and co-founder of BioNTech.
States around the world are trying to increase local vaccine production to ensure access to supplies after several manufacturing setbacks that have slowed the COVID-19 vaccination campaign in some countries.
(Reporting by Caroline Copley; Editing by Maria Sheahan and Louise Heavens; Translated by Darío Fernández)